Blood and Marrow Transplant

Blood and Marrow Transplant

The mission of the Blood and Marrow Transplant (BMT) program in the Taussig Cancer Institute is to provide high-quality, specialized patient care that emphasizes innovation, collaboration, research, and empathy. The leading edge 22-bed BMT floor features elements specifically designed for an immune-compromised patient population, including a centralized air-handling system, dedicated facilities for caregivers, and amenities to ease the burden of a 3- to 6-week average hospital stay. Cleveland Clinic's BMT program is accredited by the Foundation for the Accreditation of Cellular Therapy, and maintains associations with the National Marrow Donor Program, the Blood and Marrow Transplant Clinical Trials Network, the Chronic Graft vs Host Disease Consortium, the Radiation Injury Treatment Network, the SWOG, and the Center for International Blood and Marrow Transplant Research® (CIBMTR).

Survival outcomes at 100 days after transplantation are presented since they represent the time period when patients are at highest risk for complications and these outcomes are most representative of the quality of care provided by the BMT program. In the 2019 center-specific analysis performed by CIBMTR for BMT centers in the United States, observed 1-year survival for first allogeneic transplants performed at Cleveland Clinic's BMT program was 71.3%, which was within the expected range for the case mix of patients receiving their care at our program.

Survival 100 Days After Autologous Hematopoietic Cell Transplantation for Patients With Myeloma and Lymphoma (N = 144)


Cleveland Clinic's 100-day survival outcomes of 100% for patients with myeloma and 100% for patients with lymphoma are similar to national benchmarks.

Survival 100 Days After Allogeneic Hematopoietic Cell Transplantation Using Related Donor for Patients With Acute/Chronic Leukemia and Myelodysplastic Syndromes (N= 66)


Cleveland Clinic's 100-day survival outcomes of 88% of patients receiving myeloablative conditioning and 98% for patients receiving reduced intensity conditioning for related donor hematopoietic cell transplantation for acute/chronic leukemia and myelodysplastic syndromes are similar to national benchmarks.

Survival 30 Days After Chimeric Antigen Receptor T-Cell Therapy for Patients With Lymphoma and Myeloma (N = 44)



CAR = Chimeric Antigen Receptor

¹Includes patients treated with Yescarta, Kymriah, Tecartus and Breyanzi

²Includes patients treated with Abecma.

Chimeric Antigen Receptor (CAR) T-cell therapy is a type of cancer therapy that uses a patient's own modified white blood cells to kill cancer cells. Cleveland Clinic is an authorized treatment center for both of the available CAR T-cell thearpies - axicabtagene ciloleucel (Yescarta®) for adults with large B-cell non-Hodgkin lymphomas and tisagenlecleucel (Kymriah®) for children and adults up to age 25 with advanced acute lymphoblastic leukemia.